Gareth Morgan, MD, discusses where he sees the field headed for the treatment of patients with multiple myeloma.
Gareth Morgan, MD, director of Myeloma Research at NYU Langone's Perlmutter Cancer Center, discusses where he sees the field of CAR T cells headed for the treatment of patients with multiple myeloma.
While there are many treatment options available, these patients are still relapsing, Morgan says. The treatments also have many side effects, so cellular therapy could replace many of the current therapies that are available.
Cretostimogene Grenadenorepvec Shows High CR Rate in BCG-Unresponsive NMIBC
July 17th 2024Mark D. Tyson, II, MD, MPH, discussed treatment with cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ and data from the BOND-003 trial.
Read More